July 28, 2014

New Alzheimer’s Imaging Test Provides NO Benefits, Only Profits for Drug Companies

pin it button New Alzheimers Imaging Test Provides NO Benefits, Only Profits for Drug Companies

worthless ct scan New Alzheimers Imaging Test Provides NO Benefits, Only Profits for Drug Companies

by Vera Sharav
Alliance for Human Research Protection

 On Friday, April 6, the FDA approved another of Eli Lilly’s “breakthroughs” whose clinical value is questionable (at best).  The focus, in this instance, is not a therapeutic intervention, but rather a test using a radioactive imaging agent– a dye, brand name, Amyvid (florbetapir)–which is to be used in brain PET scans to identify amyloid clumps. The presence of amyloid in the brains of Alzheimer’s patients has been observed post mortem in autopsies. However, amyloid plaques have also been found in the brains of at least 20% of healthy elder adults with no cognitive problems.  Thus, the finding of amyloids doesn’t mean the person has Alzheimer’s.

Furthermore, FDA acknowledges that most doctors are not trained to interpret brain scan results–raising further doubts about the justification for its marketing approval of Amyvid.  The test will likely result in a high percentage of false-positives greatly expanding the number of people mistakenly identified as having Alzheimer’s.   Such a flawed test is of no clinical value–it will increase anxiety, add confusion for seniors and their families, and it will increase healthcare costs without any benefit for patients with Alzheimer’s.

As a thoughtful comment on Forbes website points out, “(sadly) amyloid imaging does nothing to contribute in any substantive way to a change in standard or attempted management of dementia.”

The dye was developed at the University of Pennsylvania which reaped a hefty profit when Eli Lilly bought it for $800 million. News of FDA’s approval–a move, which Forbes reported, “took most people who watch pharmaceutical companies by surprise”– was accompanied by flim flam hypein an effort to overcome its negative aspects by claiming those aspects to be positives.:  “We’re excited. The approval means that this product will finally be available to the patients who need, and can benefit from, this,” said Avid Radiopharmaceuticals’ founder and chief executive officer, Daniel Skovronsky, 39, a Penn neuropathologist.

In point of fact, Lilly nadmits in the drug’s label that:  “A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder.”
To overcome the lack of professional competence to read PET scans, the FDA worked with Eli Lilly to develop a three-hour online crash training program for doctors!!
However, the professional incompetence problem is hardly resolved.

Forbes reports that Lilly’s Amyvid prescribing label discloses that in a 59-patient study in which ALL Amyvid readers of a patient’s Alzheimer’s status–that was later determined by autopsy–got at least 5% and up to 14% of diagnoses wrong. This inconsistency indicates that the test is inaccurate, not objective, is dependent on subjective interpretation.

Though it lacks a clinical justification for its use, Amyvid has a commercial use for drug developers.
Shirley Wang of The Wall Street Journal notes that those who favor using Amyvid and similar agents currently under development have said that such technology will accelerate research by helping to identify people at high risk of developing Alzheimer’s and to enroll such people in clinical drug trials. Matthew Herper of Forbes states: “Where tests like Amyvid will obviously be very useful is in testing new drugs. If drug companies can screen out patients who are likely not to have Alzheimer’s, they are far more likely to be able to show that medicines aimed at Alzheimer’s are effective in clinical trials…. This really is a clever move by Lilly to make some profit on a research tool. ”

What an ingenious utilitarian use for a flawed, inaccurate screening test! Eli Lilly will be marketing a test–with FDA’s seal of approval–that will stigmatize and traumatize hundreds of thousands of elder people who will then be corralled to serve as free human drug testing subjects!

Eli Lilly has been enormously successful in marketing clinically useless drugs with debilitating side-effects that became blockbuster sellers, thanks to aggressive, unethical marketing tactics –Oraflex, Evista, Prozac, Zyprexa, Xigris, to name a few.

In 2001, having gained FDA approval of  Xigris for the treatment of sepsis, which it sold for $6,800, then raised to $8,000 per 4-day course of treatment,
Eli Lilly’s chairman, president and CEO, Sidney Taurel, told shareholders: “No medicine better symbolizes our mission than Xigris,” calling it “one of our industry’s genuine breakthroughs.”

But Xigris was found to be worthless for the treatment of sepsis shock–it failed to show a survival benefit.  To promote the use of Xigris, Lilly embarked on a deceptive marketing campaign to overcome negative evidence–i.e. increased bleeding and deaths in clinical trials.  Lilly’s aggressive marketing blitz included manipulating–with cash payments–a task force of 20 scientists and hospital directors charged with formulating sepsis clinical guidelines. The guidelines recommended Xigris despite negative evidence from clinical trials.  The company ultimately withdrew Xigris in 2011 after cashing in about $1 Billion.

If the FDA’s goal in its licensing determinations is to bankrupt the nation’s healthcare budget by approving worthless, all-too-often hazardous drugs, vaccines, and drug devices that undermine rather than improve health, it is doing a commendable job!

Read the Full Article Here: http://www.ahrp.org/cms/content/view/842/9/

See Also:

Coconut Oil and Alzheimer’s Disease: The News is Spreading

0 commentsback to post

Other articlesgo to homepage

Thousands Sue for Damages Against Cholesterol Drugs as Big Pharma Defends Billion Dollar Industry

Thousands Sue for Damages Against Cholesterol Drugs as Big Pharma Defends Billion Dollar Industry

The $100 billion dollar cholesterol-lowering statin drug industry is under attack, as thousands of Americans are filing lawsuits against cholesterol-lowering drugs such as Lipitor. Research continues to confirm just how dangerous these drugs are, with yet another study published recently linking increased statin drug use to type 2 diabetes. Since the study was published by the American Diabetes Association, these known risks to cholesterol-lowering drugs can no longer be denied or defended, and the lawsuits are pouring in at a rapid pace. Most of the lawsuits at this point are from women who have suffered with diabetes as a result of taking cholesterol-lowering drugs, but lawsuits over breast cancer, Alzheimer’s, liver damage and others may soon follow now that it is generally known how dangerous these drugs are.

According to statistics supplied by various law firms, there were 464 claims filed against Lipitor as of April 15, 2014, which increased to 703 by May 15, and then to 846 by June 16. As of mid-July 2014 over 959 claims have been filed for damages due to Lipitor alone. There are also many claims currently filed against Crestor, the next nearest competitor to Lipitor, and undoubtedly other similar drugs now sold under generic labels. These lawsuits now number well over 1,000, and are increasing at a rapid pace. Yet, this news is largely blacked out of the mainstream media.

700 Lipitor and Diabetes Lawsuit Claims Filed Against Pfizer

700 Lipitor and Diabetes Lawsuit Claims Filed Against Pfizer

Before its patent expired, Lipitor was the best-selling drug of all time. Lipitor, the drug that artificially lowers cholesterol, outsold almost all other drugs combined during the height of its run, before the patent ran out allowing generics to enter the market. The FDA did not issue warnings about the dangerous side effects of cholesterol-lowering drugs until after Lipitor’s patent expired.

The information here comes from an attorney, as attorneys across the nation see the economic opportunities now to sue Pfizer for damage done to millions of peoples’ health.

Veterans Kick The Prescription Pill Habit, Against Doctors’ Orders

Veterans Kick The Prescription Pill Habit, Against Doctors’ Orders

1 in 3 veterans polled say they are on 10 different medications.

While there is concern about overmedicating and self-medicating — using alcohol or drugs without a doctor’s approval — there are also some veterans who are trying to do the opposite: They’re kicking the drugs, against doctor’s orders.

Legal Child Kidnapping: Has the U.S. Become one of the Most Dangerous Places in the World for Children to Live?

Legal Child Kidnapping: Has the U.S. Become one of the Most Dangerous Places in the World for Children to Live?

The right to legal counsel, your Miranda rights, and the right to a speedy jury trial are American rights protected by our Constitution. But not in family court, where a single judge can decide whether or not you are a fit parent. Child Protection Services (CPS) has more power today than the police, sheriff, or FBI, as they can come into your home and remove your child without a search warrant or court order.

Someone who doesn’t like you, for any reason, can make a phone call and provide an anonymous “tip” with the result of you losing your children. Doctors you disagree with can call CPS and have your child removed from your home with no search warrant or court order, by simply reporting you to CPS. This is in fact happening all across America to thousands of families. It is time to put a stop to this.

Study: Insulin May Actually Accelerate Death in Type 2 Diabetes

Study: Insulin May Actually Accelerate Death in Type 2 Diabetes

In the United States, nearly 80 million people, or one in four has some form of diabetes or pre-diabetes. What’s worse, both type 1 and type 2 diabetes among children and teens has also skyrocketed. The most recent data, reveals that, between 2001 and 2009, incidence of type 1 diabetes among children under the age of 19 rose by 21 percent. Incidence of type 2 diabetes among children aged 10-19 rose by 30 percent during that same timeframe!

Statistics such as these point to two very important facts. First, it tells us that diabetes cannot be primarily caused by genetics, and secondly, it literally screams that something we’re doing, consistently and en masse, is horribly wrong, and we need to address it. A study published in the June 30, 2014 issue of JAMA Internal Medicine concluded that insulin therapy in type 2 diabetic patients may indeed do more harm than good.

read more


Get the news right in your inbox!